Taking a strategic, patient-focused view of integrating advanced therapies into healthcare. Panel style discussions will be hosted by FierceBiotech’s Editorial team, designed for a C-suite audience.
12pm – Register & Networking Lunch
1pm – Welcome address
1:15pm – Analyst presentation
1:30pm – Attracting investment while expanding your manufacturing base
2:30pm Refreshment break
2:45pm – How the embrace of alternative payment models will affect the development of future gene and cell therapies
When Novartis won FDA approval for its CAR-T, Kymriah, to treat some blood cancers last year, it struck a deal with the Centers for Medicare and Medicaid Services that allows for full payment only for patients who respond within one month. Spark also formed alternative payment deals around its gene therapy for retinitis pigmentosa, Luxturna.
What other ideas aside from pay-for-performance are being pursued? How involved is the payer community likely to be in shaping these deals going forward? And how should R&D professionals in biopharma incorporate the demand for alternative payment arrangements into the development process?
3:45pm – Additional Q&A
4:00pm – Networking Drinks
Please note: you have to register for the Phacilitate Leaders World to be eligible to attend the Advanced Therapies Summit in association with FierceBiotech
* subject to availability